Home → Research News → Ask-the-Expert Conferences: Research News → June 2007: Updates from the 2007 ASCO Annual Meeting → Replacement for AC cocktail?

Replacement for AC cocktail?

Page last modified on: November 20, 2008

Question from AmyG: Now that it's been established that AC chemotherapy only benefits women with a specific gene, or 8 percent of breast cancer patients overall, will women be tested for that gene? Will AC be replaced by another chemo cocktail in the near future? Thanks!: Answer —Nicholas Robert, M.D.: There is already evidence for replacing AC chemotherapy with TC chemotherapy, where T stands for Taxotere (chemical name: docetaxel). The reason to consider TC is that this appears to be more effective than AC without some of the toxicity associated with the anthracycline. However, in some patients, knowing whether the topoisomerase gene is abnormal means that there still may be a role for AC. This still needs to be evaluated with prospective clinical studies to make sure that we're measuring the right gene and identifying which patients benefit or not from AC.

On Wednesday, June 20, 2007, the Ask-the-Expert Online Conference was called Updates from the 2008 ASCO Annual Meeting. Generosa Grana, M.D., F.A.C.P. and moderator Nicholas Robert, M.D. answered your questions about the latest news on breast cancer screening, treatment, and side effects reported at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.

Email Updates

Stay informed about current research, online events, and more.

Meet the Experts

Generosa Grana, M.D., F.A.C.P. is the director of the Cooper Cancer Institute and heads the division of hematology/medical oncology at Cooper University Hospital.

Nicholas Robert, M.D. is a co-chair of the Breast Committee of the U.S. Oncology Research Network and also chairs the Cancer Committee and Research Committee of the Inova Fairfax Hospital's Cancer Center.